Brain
The following list provides a brief description of brain cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.
Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.
Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.
MAGMA
| Registered Title | A multi-arm multi-stage, multi-centre, phase III (MAMS) platform trial that aims to assess hypotheses against a common standard-of-care control arm for the management of people with glioblastoma. |
| Purpose | "This study aims to evaluate the use of temozolomide in different regimes for Glioblastoma. The trial is testing two changes to the usual schedule of treatment.
|
| Lay Summary | It is hoped this research will help identify if starting temozolomide earlier than usual and/or continuing treatment with temozolomide for longer than usual will improve the outcomes of people with glioblastoma and assist development of future treatments." |
| WA Trial Sites |  Medical Oncology Ph. (08) 6383 3000 |
| Links | Australia New Zealand Clinical Trials Registry |
Acknowledgements: Australia New Zealand Clinical Trials Registry
I8S-MC-JUAB
| Registered Title | A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer |
| Purpose | The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer. |
| Lay Summary | N/A |
| WA Trial Sites |  ph. 08 6382 5513 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
NUTMEG
| Registered Title | A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide Alone in Newly Diagnosed Elderly Patients With Glioblastoma (NUTMEG) |
| Purpose | The study aims to evaluate whether the combination of adjuvant nivolumab with temozolomide improves overall survival outcomes for this patient population. The outcome of the study will help determine the most effective treatment for patients with glioblastoma in the future. |
| Lay Summary | This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on overall survival in newly diagnosed elderly patients with glioblastoma.
Who is it for? You may be eligible to join this study if you are aged 65 years or above, with newly diagnosed histologically confirmed GBM (WHO grade IV glioma including gliosarcoma) following surgery. |
| WA Trial Sites |
|
| Links | US National Library of Medicine |
Ph. Acknowledgements: US National Library of Medicine
EX-TEM
| Registered Title | To determine if extended post-radiation temozolomide will improve survival outcomes in patients with newly diagnosed glioblastoma |
| Purpose | The purpose of this study is to determine if an extended use of a chemotherapy medication (temozolomide) after radiation improves survival outcome in patients with newly diagnosed brain cancer (also called a glioblastoma). |
| Lay Summary | N/A |
| WA Trial |
|
| Links | Australia New Zealand Clinical Trials Registry |
Acknowledgements: Australia New Zealand Clinical Trials Registry
OUTRUN / TROG 17.02
| Registered Title | Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases (TROG 17.02 OUTRUN) |
| Purpose | The aim of this study is to compare the effects of Osimertinib alone versus SRS plus Osimertinib on intra-cranial disease control in EGFR mutated NSCLC with brain metastases diagnosed or developed while on first line EGFR tyrosine kinase inhibitors. |
| Lay Summary | 20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with leptomeningeal disease in the phase 1 BLOOM study. Stereotactic radiosurgery (SRS) is one of the standard local treatment for patients with limited number of brain metastases. Currently, it is unclear whether adding SRS to Osimertinib will result in superior intracranial disease control in patients. |
| WA Trial |
|
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
Local HER-O
| Registered Title | A Phase II study of local therapy only (stereotactic radiosurgery and/or surgery) for treatment of up to 5 brain metastases from HER2 positive Breast Cancer (TROG 16.02 Local HER-O) |
| Purpose | The purpose of the study is to determine; 1. How likely the tumour/s are controlled after treatment with local therapies Neurosurgery (NS) and/or Stereotactic Radiosurgery (SRS). 2. How likely is it that other tumours develop at new sites in the brain when no Whole Brain Radiotherapy (WBRT) is given. |
| Lay Summary | For patients who have HER2 positive breast cancer which has spread to the brain (metastasised), the main treatment options for these brain metastasis are Whole Brain Radiotherapy (WBRT), Stereotactic Radiosurgery (SRS) and Neurosurgery (NS) Participants will be given either SRS or surgery or a combination of both depending on the particular features of each tumour. |
| WA Trial SItes |
|
| Links | Australia New Zealand Clinical Trials Registry |
Acknowledgements: Australia New Zealand Clinical Trials Registry
ROAM
| Registered Title | Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial |
|
| Purpose | Although benign meningiomas are slow growing, others can grow more quickly and have a higher chance of coming back. These are called atypical meningiomas. Doctors think that giving radiotherapy after surgery might stop them growing again. But they aren't sure, so want to find out more.
In this trial, some people have radiotherapy after surgery and some don't. Instead, they have regular check ups to see how they are getting on. This is called active monitoring. |
|
| Lay Summary | The aims of the trial are to:
find out if radiotherapy stops atypical mengiomas coming back |
|
| WA Trial Sites |
|
|
| Links | Cancer Research UK |
Acknowledgements: Cancer Research UK
[Return to List of Clinical Trials]
